Introduction
Primary mediastinal large B-cell lymphoma is now a well recognized clinico-pathological entity.
Histologically, the tumour is characterized by a diffuse proliferation of large B cells with clear cytoplasm and by the presence of a variable degree of sclerosis which causes the typical compartmentalization pattern [1] [2] [3] .
Primary B-cell lymphoma of the mediastinum also shows distinct clinical features, occurring in young adults, mostly women, with symptoms of a rapidly enlarging mass of the upper anterior mediastinum, complicated by superior cava vein compression and infiltration of adjacent organs and structures (lung, pleura, pericardium, chest wall) [4, 5] . Extrathoracic spread is uncommon at diagnosis. At relapse or progression, extrathoracic diffusion tends to involve unusual sites such as kidney, breast, adrenal cortex, and ovaries [4, [6] [7] [8] .
In the present study we report a series of 37 consecutive patients with primary mediastinal large B-cell lymphoma (MLBCL) with sclerosis treated in our institution since 1991, focusing on the clinical features at presentation and the response to two different thirdgeneration regimens and involved field radiation therapy (IFRT).
Patients and methods
Between August 1991 and December 1996, 37 consecutive patients, aged 15 to 60 years, with histologic diagnoses of MLBCL with sclerosis, were observed at our institution.
The histologic diagnosis was made according to the criteria described by Menestrina et al. [2] and since 1994 according to R.E.A.L. Classification [3] . The diagnostic material was obtained through thoracotomy or mediastinoscopy in 29 patients; in eight cases biopsies from supraclavicular lymph nodes were available for diagnosis. Immunohistochemical analysis of all specimens on paraffin sections and, when available, also on cryostat sections, demonstrated the B-cell origin of this type of lymphoma.
Patients were clinically staged according to the Ann Arbor classification. Bulky disease was defined as a mass measuring > 10 cm in its largest diameter.
The clinical patient characteristics at presentation are summarized in Table 1 . 
Results

Treatment
The first cohort of 10 patients was treated between August 1991 and June 1993 with the F-MACHOP regimen [9] . Of four of nine patients who obtained partial remissions (PR), F-MACHOP was followed as consolidation therapy in two by IFRT, in one by autologous bone marrow transplantation (ABMT) and in the fourth by a second-line chemotherapy with high-dose epirubicine and cytarabine. A second cohort of 27 patients was treated between June 1993 and December 1996 initially in a pilot study (nine patients) and then in a prospective multicenter trial (18 patients) between June 1993 and December 1996 with the MACOP-B regimen [10] combined with IFRT.
Radiation therapy was started approximately four to six weeks after the last cycle of chemotherapy. A 6-MV linear accelerator was used. Radiation therapy was limited to original sites of involvement with a dose of radiation ranging from 30 to 35 Gy over four to five weeks on a schedule of 180 cGy/day for five days per week.
Toxicity was assessed according to the WHO system. Oral antiinfective prophylaxis with co-trimoxazole was given to all patients during treatment.
Assessment of response
All patients were restaged with chest abdominal and pelvic CT two to four weeks after completion of chemotherapy. Therefore, the 24 patients treated with IFRT after chemotherapy were restaged with chest CT about one month after completion of radiotherapy.
67
Gallium scan was routinely performed pre-and post-radiotherapy in the last 18 patients.
Complete remission (CR) was defined as the disappearance of all detectable signs of the disease lasting longer than three months. Partial remission (PR) was defined as a reduction by at least 50% of the measurable tumour. No response (NR) was defined as less than 50% reduction of the measurable tumour, or progression of the disease, or transient disease regression lasting less than one month.
Statistical analysis
Analysis was based on patient status as of December 1997. Overall survival (OS) and progression-free survival (PFS) curves were calculated according to the Kaplan-Meier method. The effect on OS and PFS of the type of treatment (F-MACHOP vs. MACOP-B) was assessed according to the log-rank test. All /"-values are referred to two-tailed tests.
F-MACHOP regimen
All of the 10 patients (100%) in the F-MACHOP group obtained responses: one CR and nine PR. Four of the 10 patients (40%) showed disease progression after response durations of two, five, six and seven months, respectively, and underwent salvage treatment. All of these patients were in PR after the F-MACHOP regimen and received no consolidation treatment. Salvage treatment was effective in only one patient who is alive in stable partial remission (SPR) after 59 months. The remaining three patients died of progressive lymphoma. At the last update, seven patients were alive with a mean follow-up of 52 months: one of them in continous complete remission (CCR) and 6 in SPR.
MACOP-B regimen
One of the 27 patients treated with MACOP-B failed to respond (3.7%) and died of progressive lymphoma. All of the 26 (96.3%) responders obtained partial remissions after chemotherapy. IFRT was performed in 24 of 27 estimated patients. Three patients received no IFRT, two because of rapid progression after MACOP-B chemotherapy and one because of refusal. Three of the 24 patients treated with combined chemotherapy and IFRT achieved CR after completion of IFRT.
67 Ga scan, routinely performed pre-and post-radiotherapy in 18 patients, showed persistent Gallium 67 avidity in 16 patients after chemotherapy and in only four patients after IFRT. Only two of the 26 responders (7.6%) showed disease progression after a response duration of two and 12 months. Both received salvage treatment without obtaining response and died of lymphoma progression. At the last update, 24 patients were alive without disease at a mean follow-up of 27 months, three of them in CCR and 21 in SPR.
The overall survival (OS) is 70% in the F-MACHOP group at a mean follow-up of 52 months, and 93% in the MACOP-B group at a mean follow-up of 27 months (P = n.s.). The progression-free survival (PFS) is 60% in the F-MACHOP group at a mean follow-up of 38 months, and 91% in the MACOP-B group at a mean follow-up of 23 months (P < 0.02, Figure 1) .
Data on toxicity were assessable in all treated patients. Both chemotherapy regimens were well tolerated on an outpatient basis. No treatment-related toxic deaths were observed.
patients [13] . Persistent Gallium avidity was observed in 16 patients after chemotherapy and in only four patients after IFRT, suggesting that consolidation radiotherapy may have a role to play in the MLBCL treatment strategy. However, only a prospective randomized trial can define the real role of radiation therapy in this disease. A longer follow-up and confirmation of our results in the ongoing multicentric trial will enable us to confirm the primary role of a third-generation regimen such as MACOP-B plus IFRT in the treatment of primary MLBCL with sclerosis.
Discussion
In the past decade many authors have reported this entity as being characterized by a very aggressive course and poor response to conventional chemotherapy regimens [6] [7] [8] . More recently some authors have confirmed these findings but claimed that third-generation regimens (MACOP-B and VACOP-B) may induce complete remission and possible cure of this type of lymphoma in a high percentage of patients [4, 5, 11, 12] .
In our study the MACOP-B regimen yielded a response rate (CR/PR) of 96.3% and a PFS of 91% at a mean follow-up of 23 months. The response rate for the F-MACHOP group was 100%, with a PFS of 60% at a mean follow-up of 38 months. The difference between PFS curves was statistically significant with a /"-value <0.02 ( Figure 1 ). Our study confirms the favorable results reported by other authors [4, 5, 11, 12] with MACOP-B or MACOP-B-like regimens.
Based on these results and previous ones [12] , MACOP-B regimens given on an outpatient basis and delivered in a short period of time can be considered superior to F-MACHOP in treating primary MLBCL with sclerosis. As regards consolidation IFRT, because of bulkiness, it is a common practice to administer it in this type of lymphoma after response to chemotherapy [11] [12] [13] 19] . The role of IFRT in the eradication of the disease is difficult to assess. In our series, the majority of the patients had residual radiographic mediastinal abnormalities of uncertain significance at completion of chemotherapy and were considered to be in PR. Restaging of the disease pre-and post-RT showed that these radiographic abnormalities had disappeared in only three cases that were then considered as being in CR. Furthermore, only one patient out of 26 (4%) treated with consolidation mediastinal RT showed progressive disease compared to six of 11 (54%) of the patients who had not received mediastinal RT (P -0.0003) independently of the initial chemotherapy regimen. All patients relapsed or progressed also in the thorax region. However, residual mediastinal mass after chemo-and/or radiotherapy does not necessarily represent active disease. In fact, among patients with apparently incomplete response, the majority remained free of disease and will probably be cured. 67 Ga scan could discriminate residual fibrotic tissue from active tumour and was administered pre-and post-radiotherapy in 18 of our
